An excess risk of heart failure (HF) persists in patients with type 2 diabetes (T2D) despite optimal control of an array of conventional risk factors, including hyperglycaemia. Twelve cardiovascular outcome trials (CVOTs) have been published to date, although none, with the exception of the DECLARE trial with dapagliflozin, has included HF as a primary endpoint. The four trials with dipeptidyl-peptidase inhibitors (DPP-4i) (SAVOR-TIMI 53 with saxagliptin, EXAMINE with alogliptin, TECOS with sitagliptin and CARMELINA with linagliptin) failed to show any significant effect on HF risk in patients with T2D, with the notable exception of saxagliptin which was associated with a 27% increased risk. Five completed CVOTs with the GLP-1 RAs lixisenatide (ELIXA), liraglutide (LEADER), semaglutide (SUSTAIN-6), exenatide once weekly (EXSCEL) and albiglutide (HARMONY) also failed to reveal any significant effect on HF risk. The three trials with sodium glucose co-transporter-2 inhibitors (SGLT-2i) (EMPA-REG OUTCOME with empagliflozin, CANVAS with canagliflozin and DECLARE with dapagliflozin) all revealed a robust and significant reduction in the hazard ratios of hospitalization for HF, from 27% to 35%, which remained consistent, significant and of similar magnitude regardless of the presence of a history of HF or established atherosclerotic cardiovascular disease. There is no association between reductions in HF risk and haemoglobin A1c (A1C) levels, while there is a significant association between reductions in HR for MACE and A1C levels (Spearman's correlation, r = 0.695; P = 0.013). All of the 12 CVOTs completed to date have provided reassurance of the overall cardiovascular safety of the newer anti-hyperglycaemic drugs. At present, the robust, consistent and reproducible reduction of approximately 30% in the risk of HF with SGLT-2i may be considered a class effect. The beneficial effect on MACE outcome observed with the use of some GLP-1RAs and SGLT-2i must be interpreted within the frame of the single trial.
| INTRODUCTION
The goals of treatment for type 2 diabetes (T2D) are to prevent or delay complications and to maintain quality of life; this requires, above all else, control of glycaemia and cardiovascular risk factor management. 1 However, the proportion of diabetic patients achieving a haemoglobin A1C (A1C) target less than 7% continues to remain approxiately 50%. 2 Moreover, only 14% of patients meet targets for glycaemic control, blood pressure, cholesterol levels or abstinence from smoking. 3 In addition to these frustrating results, there seems to be a progressive difficulty in maintaining optimal glycaemic control in patients with T2D. Both European 4 and US 5 studies agree that achievement of the suggested A1C target of less than 7% is most frequent in patients receiving one oral drug (47%-62%) and is least frequent among patients receiving three or more oral drugs (13%) or injectable drugs (36%) in the form of insulin or a glucagon-like peptide 1 receptor agonist (GLP-1 RA). T2D is a progressive disease and the addition of other drugs, either oral or injectable, is very often needed to control glycaemia. 11 and VADT (Veterans Affairs Diabetes Trial). 12 According to the meta-analyses, more intensive glucose control led to a significant but modest reduction in major cardiovascular events (MACE), accompanied by a significant reduction in both kidney and eye events. Concerning cardiovascular complications, residual vascular risk is 91% for MACE and 100% for heart failure (HF). Thus, 9% of the risk of MACE is eliminated after achievement of the best possible glycaemic control in patients with T2D and the risk of HF is not influenced at all (Table 1) .
| RESIDUAL VASCULAR RISK
Short duration of trials may account, in part, for these unsatisfactory effects, as follow-up examinations have revealed both survival and cardiovascular benefits of tight glycaemic control in the long term (UKPDS legacy). 13 In the UKPDS 80 trial, 13 3277 patients were asked to attend annual UKPDS clinics for five years, but no attempts were made to maintain previously assigned therapies. Despite early loss of glycaemic differences, a continued reduction in microvascular risk and emergent reductions in risk of myocardial infarction and death from any cause were observed during a 10-year post-trial follow-up period.
In the present review, we assess current evidence regarding the effects of newer glucose-lowering agents on HF risk in patients with T2D. used were "CVOTs," "dipeptidyl-peptidase inhibitor," "saxagliptin,"
"alogliptin," "sitagliptin," "linagliptin"; "glucagon-like peptide-1 receptor agonist," "exenatide," "lixisenatide," "liraglutide," "semaglutide,"
"dulaglutide," "albiglutide"; "sodium-glucose co-transporter-2
inhibitor," "empagliflozin," "canagliflozin," "dapagliflozin"; "hospitalization for heart failure," and MACE (Major adverse cardiovascular events in numerous trials and is therefore contraindicated in patients with preexisting HF. For insulin and sulfonylureas, no results from prospective HF trials are available, although some evidence suggests an increased risk of HF as the result of mild fluid retention. 19 Death as the result of major cardiovascular disease has significantly and clinically relevantly decreased (−40.3% for ischemic heart disease and −29.2% for stroke) in adults with and without diabetes from 1988 to 2015 in the USA. 20 However, there was no significant change in rates of HF during the same period, and demonstrating a paradoxical increase (+11%) in young adults. These US data are coherent with Swedish data, 21 indicating that patients with T2D who succeeded in controlling five variables to optimal values (A1C <7%, LDL cholesterol <97 mg/dL, BP <140/90 mmHg, absence of albuminuria and abstiance from smoking) were at the same risk of death, stroke and myocardial infarction (MI) as the general population, but were at substantially higher risk (+45%) of hospitalization for HF. Thus, an excess risk of HF persists in patients with T2D, despite optimal control of an array of conventional risk factors, suggesting that current therapeutic strategies may not be sufficient to reduce the burden of HF in T2D.
| NEWER ANTI-HYPERGLYCAEMIC DRUGS AND RISK OF HF
Never before have clinicians had such a broad armamentarium of antihyperglycaemic drugs that can be used as first-, second-, and third-line therapies for the control of hyperglycaemia in T2D. zation for heart failure were even increased. 32 Furthermore, in some CVOTs with GLP-1 RAs, patients with advanced HF at baseline were excluded. Thus, the trials cannot provide information concerning the safety of these drugs in such patients. Bearing in mind that, in patients with advanced HF, control of heart rate is a major therapeutic principle, the significant rise in heart rate observed with all GLP-1 RAs might be considered rather deleterious in such patients. 33 However, based on current trial evidence, this potentially increased risk does not seem to extend to the earlier stages of HF, NYHA 1 and 2.
The three trials with SGLT-2i (EMPA-REG OUTCOME with empagliflozin, 34 CANVAS with canagliflozin 35 and DECLARE with dapagliflozin 36 ) all revealed a robust and significant reduction in the hazard ratios of hospitalization for HF, from 27% to 35% (Figure 3 ).
The effect of SGLT-2i on the risk of HF remained consistent, significant and of a similar magnitude, regardless of the presence of a history of HF or established atherosclerotic cardiovascular disease (ASCVD) at baseline (Figure 4 ). The benefit of HF risk reduction ranged from 49% to 29%, respectively, in patients with or without HF at baseline in the CANVAS trial, 37 and from 36% to 22%, respectively, in patients without or with ASCVD at baseline in the DECLARE trial.
38
The glucose-lowering effect of SGLT-2i is, through promotion of is less than adequate. 1 Given the caveat that the multiple and post hoc analyses of HF within the CANVAS Program, EMPA-REG OUTCOME and DECLARE trials had limited statistical power to test for interactions, coupled with the risk of observing spurious chance differences, the class of * indicates significant difference vs placebo. Abbreviations: CAN, CANVAS trial; DEC, DECLARE trial; EMP, EMPA-REG OUTCOME trial; HR, hazard ratio FIGURE 4 Risk of HF in CVOTs trials with SGLT-2i, divided according to presence/absence of heart failure (HF) and atherosclerotic cardiovascular disease (ASCVD). Gray zone represents the range of risk reduction: 49% to 21% reduction in risk in the CANVAS trial, with or without HF at baseline SGLT-2i is also promising for reduction of the risk of hospitalization for HF in T2D patients with multiple risk factors, without overt ASCVD and without history of HF at baseline.
| NEWER ANTI-HYPERGLYCAEMIC DRUGS AND RISK OF MACE
The primary endpoint of all CVOTs studies was MACE, in line with FDA guidance for excluding an excess in the risk of cardiovascular mortality, non-fatal myocardial infarction and non-fatal stroke associated with the use of newer anti-hyperglycaemic drugs in patients with T2D. Therefore, a short summary of their effect on MACE seems indicated. Overall, DPP-4i use was associated with a neutral effect on MACE in each trial (Figure 1 ), ranging from a nonsignificant 4% reduction in risk in the EXAMINE trial to a 2% enhancement of risk in the CARMELINA trial. Three (LEADER, SUSTAIN-6 and HARMONY) out of the five trials with GLP-1RAs revealed a significant reduction in the risk of MACE, ranging from a 26% reduction in the SUSTAIN-6 trial to a 22% reduction in the HARMONY trial (Figure 2 ). The ELIXA trial was the only one within the GLP-1 RA class associated with a larger number of MACE in the active treatment group with lixisenatide. This may be explained by differences in the enrolled population compared to other trials, that is, patients with a recent acute coronary syndrome event, patients of a younger age or patients with a shorter duration of diabetes. Considering the short half-life of lixisenatide (approximately 3.5 hours), it can be assumed that insufficient drug levels were in circulation for the majority of the day. Two (EMPA-REG OUTCOME and CANVAS) among the three SGLT-2i trials revealed a similar significant reduction in the risk of MACE (14%), while in the other trial (DECLARE) the risk was reduced by a nonsignificant 7% (Figure 3 ).
The consistency of reduced numbers of MACE events in four of the five reported trials with GLP-1Ras, although significant only for the LEADER, SUSTAIN-6 and HARMONYtrials, as well as in all three trials with SGLT-2i, significant only for the EMPA-REG OUTCOME and CANVAS trials, lends support to the hypothesis that the beneficial CV effects might be mediated by antiatherogenic mechanisms that decrease cardiovascular risk over time, including direct and indirect effects on the traditional CV risk factors, anti-inflammatory pathways, endothelial function, cardiac output and ischemic conditioning. 40 
| ROLE OF GLYCAEMIC CONTROL
The robust salutary effects of SGLT-2i on HF risk in patients with T2D seem to be unrelated to amelioration of glycaemic control. Several points have been made in support of this statement. First, baseline and trial-dependent changes in A1C did not seem to determine the overall benefit of SGLT-2i on HF outcome, at least in the EMPA-REG OUTCOME trial. 41 Second, the benefit concerning HF risk has been observed with a similar magnitude of risk reduction across the spectrum of renal disease, 42 suggesting a dissociation of the mechanism(s) involved in glycaemic control and cardiovascular risk reduction. Finally, the effects of SGLT-2i are also observed in individuals without T2D. 43 These interpretations are in line with the results shown in Figures 1-3 , in which the absence of a relationship between reductions in HF risk and A1C levels can be observed. More specifically, the Spearman correlation coefficient between the hazard ratios for HF risk and reduction in A1C levels in all 12 CVOTs revealed no significant association (r = 0.256; P = 0.402); hence, despite the limitations of univariate analyses, the overall effect of HF outcome may be largely independent of glycaemic amelioration. On the other hand, there was a significant association between reductions in HR for MACE and A1C levels (r = 0.695; P = 0.013); this novel finding should encourage clinicians to reconsider glycaemic control as a component of the beneficial effect of newer anti-hyperglycaemic drugs on the risk of MACE in T2D.
| CLASS EFFECT
The definition of drug class effect is based on three concepts: a similar chemical structure, a similar mechanism of action or similar pharmacological effects. 44 A class effect is, therefore, an effect produced by all members of a chemically related group of medications and not only by a single drug from that class. Conservatively, we assume that a class effect does exist when a beneficial, detrimental or neutral effect on a particular outcome is present and is significant for each drug within the class. Table 2 
| CONCLUSIONS
The evidence presented in this review is summarized in Table • Intensive glycaemic control is important for prevention and treatment of vascular complications in adults with T2D, but residual vascular risk remains high. In particular, the residual vascular risk of HF after successful glycaemic control in patients with T2D is as high as 100%.
• In patients with T2D and HF, SGLT-2i (empagliflozin, canagliflozin and dapagliflozin) reduce the incidence of hospitalization for HF, GLP-1 RAs are neutral and DPP-4i may be used with caution. Depending on the drug used (GLP-1RAs or SGLT2-i), MACE and CV mortality may also be reduced.
• The combination of newer anti-hyperglycaemic drugs (SGLT-2i or GLP-1 RAs) and optimal glycaemic control may have beneficial and additive effects on vascular complications in patients with T2D.
